Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
Stephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Alimentary Pharmacology & Therapeutics
|
June 16, 2023
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis
Geert D'Haens, Laurent Peyrin-Biroulet, Daniel J B Marks, et al.
Gastroenterology
|
May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
Severine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
Inflammatory Bowel Diseases
|
January 9, 2009
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study
Maria T Abreu, Christian von Tirpitz, Robert Hardi, et al.
The New England Journal of Medicine
|
August 23, 2013
Vedolizumab as induction and maintenance therapy for ulcerative colitis
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, et al.
Inflammatory Bowel Diseases
|
May 19, 2015
Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study
Gil Y Melmed, William M Pandak, Kevin Casey, et al.
The New England Journal of Medicine
|
August 23, 2013
Vedolizumab as induction and maintenance therapy for Crohn's disease
William J Sandborn, Brian G Feagan, Paul Rutgeerts, et al.
Journal for Immunotherapy of Cancer
|
November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
Fangwen Zou, David Faleck, Anusha Thomas, et al.
Inflammatory Bowel Diseases
|
July 12, 2016
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
Scott D Lee, David T Rubin, William J Sandborn, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
Stephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Alimentary Pharmacology & Therapeutics
|
June 16, 2023
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis
Geert D'Haens, Laurent Peyrin-Biroulet, Daniel J B Marks, et al.
Gastroenterology
|
May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
Severine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
Inflammatory Bowel Diseases
|
January 9, 2009
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study
Maria T Abreu, Christian von Tirpitz, Robert Hardi, et al.
The New England Journal of Medicine
|
August 23, 2013
Vedolizumab as induction and maintenance therapy for ulcerative colitis
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, et al.
Inflammatory Bowel Diseases
|
May 19, 2015
Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study
Gil Y Melmed, William M Pandak, Kevin Casey, et al.
The New England Journal of Medicine
|
August 23, 2013
Vedolizumab as induction and maintenance therapy for Crohn's disease
William J Sandborn, Brian G Feagan, Paul Rutgeerts, et al.
Journal for Immunotherapy of Cancer
|
November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
Fangwen Zou, David Faleck, Anusha Thomas, et al.
Inflammatory Bowel Diseases
|
July 12, 2016
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
Scott D Lee, David T Rubin, William J Sandborn, et al.
Page
of 7